Project Grant R21AA032615
Award Date 9/23/25
Completion Date 8/31/27
Dollars Obligated $404K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tennessee, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $550,417 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Texas at Austin. The grant, effective September 1, 2025 through May 31, 2030, supports research to investigate how heavy alcohol exposure in aging individuals leads to impaired microglia function, neurodegeneration, and cognitive deficits. The study aims to determine whether dysregulated neuroimmune and microglia responses are...
- This federal Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $249,000.00 to East Tennessee State University to characterize acetaldehyde-protein adducts and their effects on lymphocyte function in alcohol-associated liver disease. The research aims to investigate how the ethanol metabolite acetaldehyde forms adducts on proteins, particularly albumin, and how this modulates the pathogenesis of...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $399,076 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the University of Tennessee Health Science Center in Memphis, TN. The purpose of this grant is to develop a rapid and reliable platform for evaluating and repurposing FDA-approved drugs to target chronic alcohol tolerance and dependence associated with Alcohol Use Disorder (AUD). The project will leverage the nematode Caenorhabditis elegans as an...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $253,383 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to explore the role of the hepatocyte inflammasome in alcoholic liver disease (ALD). This research aims to investigate the liver-specific effects of the inflammasome, a key mediator of inflammation, in hepatocytes - the predominant liver cell type and a driver of ALD pathophysiology. The project will use mouse models to evaluate...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $438,375 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Cedars-Sinai Medical Center to establish a human liver-on-a-chip model for studying alcohol-associated liver disease (ALD). The 2-year project, starting September 2023, aims to investigate the roles of liver sinusoidal endothelial cells and acetaldehyde metabolism in regulating ethanol-induced liver damage as well as the contribution of fibrotic...
- This Project Grant award of $639,177.00 from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273) federal grant program, will support research to investigate the role of hepatic FOXA3 in the development and progression of alcohol-associated liver disease (ALD). The University of Arizona will conduct this research project to gain a better understanding of the mechanisms underlying the pathogenesis of ALD, which is the most prevalent...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $601,129 Project Grant under the Alcohol Research Programs (CFDA 93.273) to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University (CCLCM). The project, titled "Alcohol and Gut-Brain Axis and the Role of Butyrate on Neuroinflammation and Pain Sensitivity", aims to investigate the relationship between alcohol use disorder, chronic pain, and the gut microbiome, with a focus on the role of...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA) awarded a $1,376,398 Project Grant under the Alcohol Research Programs (CFDA 93.273) to Yale University to develop a humanized mouse model to study alcohol-associated hepatitis (AAH). The project aims to create a fully humanized mouse liver system by engrafting human hepatocytes and non-parenchymal cells to better understand the complex cell interactions that drive key features of AAH, a leading cause of liver-related deaths...
- This Project Grant award from the National Institute on Alcohol Abuse and Alcoholism (CFDA 93.273 - Alcohol Research Programs) provides $440,566 to Yale University to advance the treatment of alcohol-associated liver disease (ALD). The primary objective is to uncover therapeutic targets and develop effective ALD treatments, with a focus on the methyltransferase-like (METTL) protein family, notably METTL7A, which is highly expressed in ALD patients. The research utilizes cutting-edge technology...
- This federal Project Grant award of $3,182,397.00 was provided by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) under the Alcohol Research Programs (CFDA 93.273) to the University of California, San Diego (UCSD). The grant aims to characterize the role of host gut proteases, particularly cathepsin B, and the immune response in alcohol-associated liver disease (ALD) in both a human cohort and a mouse model. The research seeks to determine how alcohol-mediated induction of...